FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins.
Intellia
⚠️ 风险分析 中
摘要：FDA解除对Intellia基因编辑疗法关键试验的部分暂停，需关注合规风险。
影响：企业需确保临床试验数据合规、患者隐私保护及知识产权管理，以避免监管处罚或试验再次中断。
建议：加强临床试验数据管理和隐私保护，持续监控FDA监管要求，确保合规运营。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.